CardioMech is focused on developing innovative therapeutic options for heart disease, particularly targeting mitral regurgitation, a prevalent cardiovascular condition characterized by the backward flow of blood across the mitral valve. The company has designed a unique device that functions as an artificial chord, aimed at reducing or eliminating this regurgitation while restoring the heart's native anatomy. This catheter-based therapy is intended to provide a less invasive alternative to traditional open-heart surgery, making it suitable for patients who are either eligible for surgery or considered ineligible due to various health factors. The potential market for this device is significant, projected to surpass the current $6 billion TAVR market.

The CardioMech device represents a promising advancement in the treatment of mitral regurgitation, offering a straightforward procedural approach that could minimize the need for more invasive surgical interventions. By addressing the condition effectively, the device may also reduce the necessity for prolonged monitoring in younger and healthier patients who might otherwise be subjected to watchful waiting. However, it is important to note that the CardioMech device is currently classified as an investigational device, which limits its use to investigational purposes only.

Norway

CardioMech is a medical device company that is developing a transfemoral, transseptally delivered mitral valve chordal repair technology to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or other structural abnormalities.

CardioMech

Company Details